Einzelnachweise

    1. ↑ Leary SM et al. Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 2003; 206:215-6.
    2. ↑ Montalban X Effects of IFNß in PPMS. Mult Scler 2003; 9: S18.
    3. ↑ 3,0 3,1 Wolinsky JS et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61:14-24.
    4. ↑ Pöhlau D et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007; 13(9):1107-17.
    5. ↑ Hawker K et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4):460-71.
    6. ↑ 6,0 6,1 6,2 Montalban X et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (ORATORIO). N Engl J Med 2016